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1. Introduction
Apitoxin, also known as bee venom (BV), is produced in two spe-
cialized abdominal glands of worker bees and is used as a defence
weapon of bees’ colony (Choi et al., 2015; Zhang et al., 2016). In ad-
dition, this natural product has been used since the ancient times to
relieve pain and to treat chronic inflammatory diseases such as rheu-
matoid arthritis, tendinitis, bursitis, skin conditions and even neuro-
logic disorders (Moreno and Giralt, 2015).
This natural product is a light-yellow liquid, characterized by a bitter
taste, pungent smell and a pH ranging from 4.5 to 5.5 (Eze et al., 2016;
Hossen et al., 2017). Some studies have described that 88% of BV is
water, yet its specific composition varies depending on bee’ species and
season (Moreno and Giralt, 2015). Indeed, BV has been reported to
contain a complex of biologically active compounds among which en-
zymes (phospholipase A2 [PLA2], lysophospholipase, hyaluronidase, acid
phosphomonoesterase; α-glucosidase, dipeptidyl peptidase IV and vi-
tellogenin), peptides (melittin [MLT], apamin, mast cell degranulating
[MCD], mastocytolytic peptide, scapin, adolapin, minimine; apidaecin;
tertiapin; melittin F; cadiopep; procamine A, B, pamine, and protease-
inhibitors), biogenic amines (histamine, dopamine, noradrenaline, nor-
epinephrine, neurotransmitters) and other compounds such as amino
acids (γ-aminobutyric acid, α-amino acids), carbohydrates (glucose,
fructose), pheromones (Iso-pentyl acetate, n-buttyl acetate, iso-pentanol,
n-hexyl acetate, n-octyl acetate, 2-nonanol, n-decyl acetate, benzyl
acetate, benzyl alcohol and (2)-11 –eicosen-1-ol) and minerals (P, Ca and
Mg) (Nguyen et al., 2015; Tusiimire et al., 2015; Rady et al., 2017; Moga
et al., 2018; Lee et al., 2018). Among these compounds, MLT is the main
therapeutic ingredient of BV, representing between 40 and 60% of the
dry weight (Abd-Elhakim et al., 2014).
However, it is important to take into account that some BV con-
stituents (such as PLA2, lysophospholipase, hyaluronidase, MLT,
apamin and MCD) can exert toxic effects, leading to clinical signs and
symptoms of envenomation. On the other hand, other compounds, like
phosphatase and α-glucosidase, are non-toxic (Cornara et al., 2017).
BV may be obtained from the beehives using electric stunning de-
vices. After, impurities and residues are removed and the remaining
purified compound is lyophilized (Han et al., 2013a). In nature, bee
venom may be injected into the victims through bees’ sting and the
amount of venom per sting ranges between 50 and 140 μg (Moreno and
Giralt, 2015). The responses of the human organism include local and
limited or systemic and extensive inflammatory reactions, immune re-
sponses and anticoagulant effects (Eze et al., 2016; Cornara et al.,
2017).
The most successful drugs developed by the pharmaceutical in-
dustry have been isolated from plants, microbes and marine organisms
(Ratcliffe et al., 2014). However, only around 900 pharmaceutical
products for human usage have been isolated from insects (Hassan
et al., 2015). Regarding BV, the majority of the published works are
preliminary studies developed in vitro and in vivo using animal models,
mostly mice, while little evidence comes from studies performed di-
rectly to prove BV therapeutic activities in humans.
Therefore, this review aims to outline the published literature re-
garding the pharmacological properties and medical applications of
Apitoxin and its bioactive compounds as well as to summarize some of
the health concerns related to its application.
2. Bioactive compounds of bee venom and their biological effects
Recently, the investigation of bioactive compounds isolated from BV
has attracted the attention of several researchers. The majority of the
published reports aims to investigate the pharmacological properties of
BV components using cell cultures or in animal models, while very little
information comes from studies involving humans (Komi et al., 2018).
Table 1 summarizes the therapeutic activities of peptides, enzymes and
biogenic amines contained in Apitoxin.
https://doi.org/10.1016/j.fct.2019.110864
Received 25 August 2019; Received in revised form 26 September 2019; Accepted 27 September 2019
Abbreviations: BV, Bee venom; CNS, Central Nervous System; COX, Cyclooxygenase; MCD, Mast-Cell-Degranulating peptide; MLT, Melittin; PLA2, Phospholipase A2
∗ Corresponding author. Department of Biology and Biotechnology, Agricultural College of Bragança, Polytechnic Institute of Bragança, Campus Santa Apolónia,
5300-253, Bragança, Portugal.
E-mail address: leticia@ipb.pt (L.M. Estevinho).
Food and Chemical Toxicology 134 (2019) 110864
Available online 28 September 2019
0278-6915/ © 2019 Published by Elsevier Ltd.
T
2.1. Peptide components
2.1.1. Melittin
Melittin (MLT), also known as allergen Api m4 (Hossen et al., 2017),
is the main compound of BV, comprising approximately 40–60% of its
dry weight. MLT (together with apamin) has been reported to be found
only in bee venom produced by the genus Apis (Moreno and Giralt,
2015). It is a linear, amphipathic, cationic and a-helical polypeptide
molecule composed of 26 amino acid residues and is soluble in water
(Silva et al., 2015; Kachel et al., 2018).
Recent studies provided evidence on several biological properties of
MLT (Table 1). MLT has been reported to be a very potent anti-
inflammatory agent, being 100 times more potent than hydro-cortisol
in animal models (Vick and Shipman, 1972; Eze et al., 2016). The anti-
inflammatory activity of this compound has been explored in several
settings, including acne vulgaris, neuro inflammation, atherosclerosis,
arthritis and liver inflammation (Lee and Bae, 2016).
Its ability to disrupt lipid cell membranes and antimicrobial prop-
erties has also attracted great interest, especially for the treatment of
drug-resistant infections (Choi et al., 2015; Cornara et al., 2017;
Nguyen et al., 2015; Uddin et al., 2016). These authors also observed
that MLT significantly inhibits the replication of both enveloped [me-
littin molecules fuses with viral envelope, forming pore-like attack
complexes] and non-enveloped viruses, decreasing their infectivity
Table 1
Bioactive compounds of bee venom and their implications in human health.
Bioactive compounds Biological activities References
MLT Anti-cancer (solid tumours) Li et al. (2006); Liu et al. (2016a); Ip et al. (2012); Jeong et al. (2014); Jin et al. (2018); Jo et al.
(2012); Kong et al. (2016); Mahmoodzadeh et al. (2015); Moreno and Giralt (2015); Rady et al.
(2017); Ratcliffe et al. (2014); Shin et al. (2013); Su et al. (2015); Zarrinnahad et al. (2018); Park et al.
(2010); Lee et al. (2018); Wang et al. (2009); Wang et al. (2017); Zhang et al. (2014); Zhang et al.
(2016) Zhang and Chen (2017)
Anti-cancer (hematologic malignancies) Saini et al. (1999); Moon et al. (2006)
Anti-atherosclerotic Jeong et al. (2012); Cho et al. (2013)
Anti-arthritis Jeong et al. (2015)
Anti-inflammatory Ip et al. (2012); Jeong et al. (2014); Jin et al. (2018); Jo et al. (2012); Kong et al. (2016); Leandro et al.
(2015); Liu et al. (2016a); Mahmoodzadeh et al. (2015); Moreno and Giralt (2015); Rady et al. (2017);
Su et al. (2015); Zarrinnahad et al. (2018)
Antibacterial Ip et al. (2012); Jeong et al. (2014); Jin et al. (2018); Jo et al. (2012); Kong et al. (2016); Liu et al.
(2016a); Mahmoodzadeh et al. (2015); Rady et al. (2017); Su et al. (2015); Zarrinnahad et al. (2018);
Leandro et al. (2015); Moga et al. (2018); Shi et al. (2016); Shin et al. (2017)
Antiviral Hood et al. (2013); Jallouk et al. (2014); Leandro et al. (2015); Moga et al. (2018); Wachinger et al.
(1998)
Pro-apoptotic Yang et al. (2007); Han et al. (2014); Lee et al. (2014); Leandro et al. (2015); Kim et al. (2018); Moga
et al. (2018)
Analgesic Ahn et al. (2016)
Anti-fibrotic Shin et al. (2017)
Anti-diabetic Hossen et al. (2017)
Haemolysis Tosteson et al., (1985)
Neuro-protective Han et al. (2014)
Apamin Antifungal Shin et al. (2017)
Anti-fibrotic Park et al. (2014)
Anti-cancer (solid tumours) Ratcliffe et al. (2014)
Anti-inflammatory Kim et al. (2017a); Shin et al. (2017)
Anti-atherosclerotic Kim et al. (2015)
Antibacterial Leandro et al. (2015)
Suppresses biliary fibrosis Kim et al. (2017b)
PLA2 Antibacterial Boutrin et al. (2008); Leandro et al. (2015)
Anti-arthritis Eze et al. (2016)
Anti-trypanosomiasis Boutrin et al. (2008)
Neuroprotective Jeong et al. (2011)
Anti-malarial Deregnaucourt and Schrével (2000)
Anti-cancer Ratcliffe et al. (2014); Wang et al. (2009)
Anti-HIV Fenard et al. (2001), Ratcliffe et al. (2014)
Secapin Antifungal Lee et al. (2016a)
Antibacterial
Anti-elastolytic
Anti-fibrinolytic
Adolapin Anti-inflammatory dos Santos-Pinto et al. (2018); Moga et al. (2018); Nitecka-Buchta et al. (2014); Komi et al. (2018)
Anti-nociceptive
Anti-pyretic
Apidaecin Antibacterial Li et al. (2006a); Van Vaerenbergh et al., (2013)
Protease inhibitor Antibacterial Eze et al. (2016)
Anti-inflammatory
Haemostasis
Tertiapin Inward-rectifier K+ channel block Cornara et al. (2017)
Cardiopep Beta adrenergic blocker, anti-arrhythmic Moreno and Giralt (2015); Vick et al. (1974)
Mast cell degranulation, histamine release Moga et al. (2018)
Anti-inflammatory Eze et al. (2016); Moreno and Giralt (2015)
Allergic response and Hypersensitivity dos Santos-Pinto et al. (2018)
Enhance the noxious action of substances Reitinger et al. (2008)
Use in BV immunotherapy Hossen et al. (2016)
Embryogenesis; angiogenesis, diffusion of toxins
and drugs, metastasis
Bordon et al. (2015)
Histamine Allergic response Eze et al. (2016)
Local and systemic inflammation
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through surface charge interaction.
This compound is also cytotoxic against cancer cells among other
mechanisms through the activation of apoptotic pathways (both cas-
pase-dependent and caspase-independent) and PLA2 pathways (Lee
et al., 2018; Jin et al., 2018; Shin et al., 2017; Zhang and Chen, 2017;
Wang et al., 2017). Indeed, the growth inhibitory potential and the
capacity to suppress tumour metastasis of MLT has been observed in
several types of cancer cells like liver, renal, prostate, breast, lung,
bladder, gastric and leukemia, suggesting that it may be a potent agent
to use in chemotherapy (Liu et al., 2016; Moreno and Giralt, 2015;
Kong et al., 2016).
Melittin has also been shown to induce neural plastic changes in
pain-signalling pathways by sensitization and activation of nociceptor
cells (Wehbe et al., 2019).
A schematic representation of the action mechanisms of some bio-
logical effects of MLT (anticancer, anti-inflammatory, antimicrobial and
anti-nociceptive) are presented in Fig. 1.
In spite of the promising properties that are attracting much interest
from pharmacological and biotechnological fields, MLT (whose initial
structure is helical, when embedded in a lipid bilayer) can change to a
dimeric form that destabilizes and alters artificial lipid bilayers con-
taining dioleoylphosphatidylcholine (Somwongin et al., 2018). There-
fore, MLT may induce morphologic changes in a dose-dependent
manner, being a nonselective cytolytic peptide that may induce the lysis
of red blood cells and human peripheral blood lymphocytes, among
others (Gajski et al., 2016). Indeed, while in small doses MLT has anti-
inflammatory effects, increases capillary permeability, in higher doses
it may cause inflammation, itching, irritation and local pain (Lee and
Bae, 2016). According to the literature, this compound may cause
slight, moderate and severe irritation at 0.5 mg/ml, 1mg/ml and con-
centrations above 2mg/ml, respectively (Somwongin et al., 2018). The
mechanism underlying toxicity is based in the disruption of phospho-
lipid bilayers which lead to mast cells’ lysis and the release of com-
pounds like lysosomal enzymes, histamine and serotonin, triggering
pain and inflammation. Therefore, MLT together with hyaluronidase
and PLA2, are responsible for venom allergenic properties breaking up
membranes cells and enhancing their cytotoxic effect (Kachel et al.,
2018).
Attempts have been made to avoid these side effects via phos-
phorylation of MLT in specific amino acid residues; the peptide phos-
phorylated in 18Ser elicited lower allergenic responses when compared
to native melittin. In addition, ongoing studies are assessing MLT in-
corporation into nanoparticles in order to decrease its the nonspecific
lytic activity (Abd El-Wahed et al., 2018).
2.1.2. Apamin
Apamin is a neurotoxin with 18 amino acid residues that comprises
2–3% of BV dry weight (Rady et al., 2017; Moga et al., 2018). As
mentioned previously, apamin and MLT are “specie specific” com-
pounds whose presence has only been reported in the BV of the Apis
genus (Moreno and Giralt, 2015). Apamin is permeable to the blood–-
brain barrier, affecting the central nervous system (CNS) and producing
hyperactivity and convulsions. It is well known that this peptide is as a
specific and high-affinity blocker of small-conductance Ca2+-activated
K+ channels (SK-channels) (Kim et al., 2017a; Zhang et al., 2018).
Peripherically, apamin selectively and potently affects the potassium
permeability of muscle cells membranes and, when in high doses, may
cause muscle spasms and respiratory failure. This characteristic has
been widely explored and apamin has been used in the literature to
identify the activity of the SK-channels in different cells such as visceral
smooth muscle, microglial cells, adrenal cortex, hepatocytes and ven-
tricle cells (Voos et al., 2017). In spite of this, recent studies demon-
strated that this compound is also capable of inhibiting the channel
Kv1.3 with high affinity (Voos et al., 2017). These two types of channel
are frequently co-expressed in different tissues among which immune
system cells (T cells, macrophages and dendritic cells).
Several researchers studied health-related applications of Apamin
(Table 1) as anti-inflammatory (Shin et al., 2017), antibacterial, anti-
fungal, anti-fibrotic (Shin et al., 2017), anti-cancer (Ratcliffe et al.,
2014), anti-atherosclerosis (Kim et al., 2015), anti-nociceptive and
Fig. 1. Schematic representation of the action mechanisms of some biological effects of melittin.
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cytotoxic against cancer cells (Son et al., 2007). It has also been re-
ported to protect undamaged neurons but also to be able to restore the
function of silent ones (Moreno and Giralt, 2015). In mice models with
cholestatic liver disease apamin suppressed the deposition of collagen
and the expression of fibrogenic genes (Kim et al., 2017b), suggesting
its role has a potential therapeutic target.
2.1.3. Mast-cell-degranulating peptide
Mast cell degranulating (MCD), also known as peptide 401,
(Cherniack and Govorushko, 2018), is another important compound
with 22 amino acids and two disulphide bridges which comprises
around 3% of BV dry weight. It promotes mast-cells degranulation,
triggering inflammatory reactions (Rady et al., 2017; Komi et al.,
2018). MCD has unique immunologic properties, causing histamine
release at concentrations of less than 0.1mg/mL while acting as an anti-
inflammatory compound at higher concentrations (Moga et al., 2018).
Indeed, MCD has been recognized as a potent anti-inflammatory agent
(Moreno and Giralt, 2015). This compound is also a neurotoxin by
blocking fast-inactivating and slow-inactivating calcium-activated po-
tassium channels (KC-channels), therefore increasing neuronal excit-
ability (Cornara et al., 2017). However, the effects in the CNS are
poorly studied (Chen et al., 2016).
2.1.4. Secapin
Secapin, comprising only 0.5–2% of BV dry weight, is a potent
neurotoxin containing 25 amino acid residues and a disulphide bridge
between Cys 9 and Cys 20 (Rady et al., 2017). It is a serine protease
inhibitor-like peptide with anti-fibrinolytic (plasmin inhibitor), anti-
elastolytic, anti-fungal and antibacterial activities; nevertheless, the
mechanisms underlying such actions are poorly understood (Lee et al.,
2016).
2.1.5. Adolapin
Adolapin is a basic polypeptide with 103 amino acid residues, re-
presenitng 0.5–1% of BV dry weight matter (Rady et al., 2017). This
compound has been reported to be anti-inflammatory, anti-nociceptive
and anti-pyretic, mainly due to the inhibition of cyclooxygenase (COX),
PLA2 and lipoxygenase, thereby, prostaglandin synthetase system, fol-
lowing a biphasic dose-response relationship (Moga et al., 2018;
Nitecka-Buchta et al., 2014; Komi et al., 2018).
2.1.6. Apidaecin
Apidaecin-type peptides are a series of small proline-rich peptides
containing 18 to 20 amino acid residues (Li et al., 2006a). This non-
helical and heat-stable compound is active against a wide range of
human pathogens and plant-associated bacteria, through a bacterio-
static process (Van Vaerenbergh et al., 2013). These compounds are the
largest group of proline-rich antimicrobial peptides known to date and
appear to be non-toxic to human and animal cells, making them po-
tential candidates for the development of new antimicrobials in the
future (Li et al., 2006a).
2.1.7. Protease inhibitor
The protease-inhibitor comprises 0.1–0.8% of BV dry weight and
has been reported to have anti-inflammatory and anti-fibrinolytic ef-
fects (Eze et al., 2016). Other studies revealed anti-microbial activity
against fungi, gram-positive and gram-negative bacteria (Yang et al.,
2017).
2.1.8. Tertiapin
Tertiapin comprises< 0.1% of BV dry weight and is a small pre-
synaptic peptide with 21 amino acids that blocks inward rectifier KC
channels expressed in heart, epithelial cells and CNS (dos Santos-Pinto
et al., 2018; Rady et al., 2017). Despite being classified as a neurotoxin
(as occurs for MCD and secapin), the information on its pharmacolo-
gical and toxicological effects in the CNS is quite limited (Chen et al.,
2016). Nowadays, tertiapin is used only for K+ channel modulation; in
the future it is expected to be useful for treating disorders in atrio-
ventricular transmission (Cornara et al., 2017).
2.1.9. Cardiopep
Cardiopep is a peptide comprising less than 0.7% of BV dry matter
(Moreno and Giralt, 2015) reported to possess beta adrenergic and anti-
arrhythmic effects (Vick et al., 1974).
2.1.10. Other peptides
Other minor constituents of BV are pamine (1–3% of dry weight
matter), minimine (2%), procamine A, B (1–2%), and melittin F, a
fragment of MLT in which the first seven residues from the N terminus
are missing (< 0.1%) (Chen et al., 2016; Rady et al., 2017).
2.2. Proteins
2.2.1. Phospholipase A2 (EC 3.1.1.4)
Phospholipase A2 has been reported to be the most abundant en-
zyme of BV, corresponding to 10–12% of its dry weight matter (dos
Santos-Pinto et al., 2018). Due to its high molecular weight and strong
antigenicity, this enzyme has been pointed as the major cause of the
systemic allergic reactions to BV (Gajski et al., 2016; Hossen et al.,
2016). On the other hand, several recent reports unveiled the potenti-
ality of PLA2 in the treatment of human disorders (Table 1) including
Parkinson's disease, asthma, several types of cancer, as well as immune
mediated disorders like cisplatin-induced nephrotoxicity, hepatotoxi-
city and Lupus nephritis (Ratcliffe et al., 2014). Its role in bacteria and
parasite infections was also described. For instance, Boutrin et al.
(2008) observed that PLA2 inhibited Gram-negative bacteria and the
parasitic protozoan Trypanosoma brucei. This study also confirmed the
antibacterial activity against Escherichia coli, Enterobacter cloacae and
Citrobacter freundii (Boutrin et al., 2008), Burkholderia pseudomallei,
Staphylococcus aureus, Streptococcus salivarius and Lactobacillus casei.
2.2.2. Hyaluronidase (EC 3.2.1.35)
Hyaluronidase is widely distributed in nature, particularly in animal
venoms such as bee, scorpion, wasp, spider, fish and crustaceans
(Bordon et al., 2015). This enzyme is composed by 350 amino acids and
specifically degrades hyaluronic acid in the extracellular matrix of skin
matrix, allowing the penetration of venom components deeply into the
blood stream (Marković-Housley et al., 2000). Other roles of hyalur-
onidase in envenoming process are cell membrane disruption, pore
formation, mast cell degranulation (dos Santos-Pinto et al., 2018), di-
latation and increased permeability of blood vessels (Hossen et al.,
2016). This enzyme is the second major allergen of BV (following
Phospholipase A2), comprising 1–2% of dry weight matter (Cornara
et al., 2017). Even though hyaluronidase has little toxicity it can en-
hance the effect of other toxins present in venoms, contributing to the
local and systemic effects of envenoming (Bordon et al., 2015).
Regarding the application of hyaluronidases for human health,
these may act as an adjuvant to enhance the absorption and dispersion
of injected drugs, be used in ophthalmologic surgeries and in the
treatment of diseases associated with excessive “ground substance”,
either applied subcutaneously or in a topical way (Reitinger et al.,
2008). These enzymes may also play a role in various physiological
mechanisms like angiogenesis, embryogenesis, metastasis formation,
cicatrisation and in several inflammatory settings like pneumonia,
meningitis and sepsis (Bordon et al., 2015).
2.2.3. Acid phosphomonoesterase (EC 3.1.3.2)
The acid phosphomonoesterase, also known as acid phosphatase, is
a glycoprotein and potent allergen found in BV, representing approxi-
mately 1–2% of its dry weight matter (Rady et al., 2017). This com-
pound has been reported as a stronger elicitor of histamine release from
basophils of sensitized humans. However, the pathophysiological role
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of this enzyme following BV inoculation remains largely unexplored.
Even so, some reports exist regarding the potential for immunotherapy
against BV (Hossen et al., 2016).
2.2.4. Dipeptidyl peptidase IV
Dipeptidyl peptidase IV (Api m 5) is present in BV in low con-
centrations (< 1% of dry weight) and has been identified as one of the
proteins of higher molecular weight (102 kDa). It appears to be re-
sponsible for the cross-reactivity between bees and wasps' venoms
(Antolín-Amérigo et al., 2017).
This proteolytic enzyme cleaves N-terminal dipeptides from poly-
peptides with proline or alanine in the penultimate position, what leads
to the activation of BV components and promotes hypersensitivity re-
actions (dos Santos-Pinto et al., 2018).
2.2.5. Vitellogenin
Vitellogenin is another allergen found in BV, present in larger
amounts in the BV secreted by honeybee queens. This enzyme is be-
lieved to be involved in several processes such as hormone signalling,
food-related behaviour, stress resistance, immunity and longevity (dos
Santos-Pinto et al., 2018), yet the underlying mechanisms remain un-
clear (Blank et al., 2013). Its role in the hypersensitive reactions has
also been reported (dos Santos-Pinto et al., 2018).
2.2.6. Other proteins
Several proteins are present in BV in low concentrations, com-
prising< 1% of its dry weight matter: Lysophospholipase (EC 3.1.1.5)
also known as phospholipase B (Hossen et al., 2016; Rady et al., 2017)
and α-D-Glucosidase (EC 3.2.1.20) (Hossen et al., 2016; Rady et al.,
2017). To date, their biological activities are poorly documented.
2.3. Biogenic amines
2.3.1. Histamine
This small molecule comprises 0.5–2% of BV dry weight matter and
is the major component among the category of biogenic amines
(Moreno and Giralt, 2015). During bee venom allergy, histamine is the
principal inflammatory mediator released immediately in the skin,
mainly mediated by mast cell degranulation peptide. This amine pro-
motes capillary leakage, causes itching, swelling and pain (Rady et al.,
2017).
2.3.2. Dopamine and noradrenaline
Dopamine and noradrenaline are also low molecular weight com-
pounds found in BV comprising<1% of its dry weight matter (Rady
et al., 2017). These compounds are ionotropic agents and have been
pointed out to be protease inhibitors, playing a role in haemostasis and
acting as anti-inflammatory agent (Nitecka-Buchta et al., 2014).
2.4. Other components
BV also contains amino-acids (like γ-aminobutyric acid and α-amino
acids), carbohydrates and pheromones (iso-pentyl acetate, n-butyl
acetate, iso-pentanol, n-hexyl acetate, n-octyl acetate, 2-nonanol, n-
decyl acetate, benzyl acetate, benzyl (Rady et al., 2017).
3. Therapeutic applications of bee venom in human health
The use of bee products (honey, pollen, propolis, bees’ wax, royal
jelly and bee venom) to treat some human illnesses is known as api-
therapy and dates back from thousands of years, with their healing
properties being cited in many religious texts (Cornara et al., 2017). BV
has been used since around 3000 BC in ancient Egypt and Greece (Yang
et al., 2017; Lee et al., 2018). Throughout the decades the use of api-
therapy expanded from the Eastern to the Western countries, being
currently practiced all over the world (El-Wahab and Eita, 2015),
mostly as a complement to the conventional medicine practices. Not-
withstanding, the understanding of the chemical composition and ac-
tions of BV dates back only 50 years ago (Moreno and Giralt, 2015).
Depending on the health condition under treatment BV can be used
topically (by applying a cream, liniment, or ointment), via injection,
either through acupuncture or directly through a live bee sting.
Currently, the most commonly used method is BV acupuncture, which
consists in the injection of diluted bee venom into acupuncture points
(Lee et al., 2015).
In the last decade, as result of increasing investigation worldwide,
the usefulness of BV has been reported for several diseases and patho-
logic contexts (Table 2), in studies performed in vitro and in vivo, in
animal models or enrolling humans. Among other settings, the effects of
BV were demonstrated in multiple sclerosis and Parkinson's disease
(Ostrovsky and Ehrlich, 2018), dementia (Silva et al., 2015), athero-
sclerosis (Lee and Bae, 2016), osteoarthritis (Lee et al., 2012), human
immunodeficiency virus (HIV) (Jallouk et al., 2014), periodontitis (Gu
et al., 2019), Diabetes mellitus (Hossen et al., 2017) and rheumatoid
arthritis (Son et al., 2007; Brito et al., 2018). The effects of BV and its
isolated bioactive compounds have also been described in several types
of solid cancer like breast, ovarian, bladder, lung, liver and prostate, as
well as on hematologic malignancies (Moga et al., 2018). Other ther-
apeutic activities described are antibacterial, anti-fibrosis and anti-
nociceptive (Cho et al., 2018; Cornara et al., 2017). One of the best
documented effects of BV is its powerful anti-inflammatory activity,
which is particularly due to the presence of melittin. Indeed, even
though BV may produce local inflammation when delivered in high
doses, when used in controlled concentrations it has potent anti-in-
flammatory effects by influencing endogenous cortisol production and
suppressing inflammatory mediators among which tumour necrosis
factor alpha (TNF-α) and interleukin 1-β (Lee and Bae, 2016). This
property is very relevant having into account the important role of
chronic inflammation in the pathogenesis of a wide range of conditions
like cardiovascular diseases, obesity and diabetes, asthma, autoimmune
disorders, inflammatory bowel disease and neurological diseases.
In addition, due to its anti-ageing properties, BV has been increas-
ingly more used in the manufacture of cosmetics products (Choi et al.,
2015). All of these biological activities are related to the presence of
some bioactive compounds mainly the MLT, PLA2 apamin, secapin,
tertiapin and MCD (Zarrinnahad et al., 2018).
In this context, this natural product and its isolated components are
valuable resources to be used in the future for the design and devel-
opment of drugs. However, besides the fact that the BV concentration
that allows maximising the beneficial effects while decreasing the ad-
verse ones remains unknown, many of the active compounds are far
from being explored (Uddin et al., 2016). In addition, the toxicity of BV
remains a big dilemma for researchers and clinicians; indeed, while
small compounds and peptides mainly mediate local reactions causing
discomfort, larger proteins are involved in direct tissue damage or in
systemic hypersensitive reactions including anaphylaxis (Jakob et al.,
2017). Thereby, yet much information is available regarding the po-
tential applications of BV, further studies must be developed to clarify
the optimum dose, its adverse effects (particularly on risk groups like
pregnant and breast-feeding women) and the possible interactions with
conventional drugs. A graphical overview of current strengths, weak-
nesses, opportunities and threats of bee venom is depicted in Fig. 2.
4. Applications of bee venom in the cosmetic industry
BV has several promising properties that aroused the interest of the
dermatocosmetic industry (Komi et al., 2018). Indeed, besides its an-
timicrobial, antibacterial and anti-inflammatory properties, some stu-
dies reported the potentiality of BV to reduce skin aging manifestations
such as skin tone changes, wrinkles, sagging and evenness (Choi et al.,
2015). Notwithstanding, the potential to cause skin irritation could be a
major concern (Somwongin et al., 2018).
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Table 2
Pharmacological activities and medical applications of Apitoxin.
Effects of bee venom References
Amyotrophic lateral sclerosis Lee and Bae (2016) [in vivo, animal models]
Anti-ageing Choi et al. (2015) [in vivo, humans; in vitro]; Han et al. (2013a) [in vivo, humans; in vitro]; Tusiimire et al. (2015) [in vitro]; Han
et al. (2015) [in vivo, humans; in vitro]; Lee et al. (2015) [in vitro]
Anti-arthritic Lee et al. (2012); Wang et al. (2002); Jeong et al. (2015); Son et al. (2007) [all studies performed in vivo, in humans];
Anti-dandruff Prakash and Bhargava (2014) [in vitro]
Anti-fibrotic Lee et al. (2015) [in vivo, animal models]
Anti-inflammatory Sobral et al. (2016); Kim et al. (2016); Mohammadi et al. (2015) [all performed in vitro]
Anti-nociceptive Cornara et al. (2017); Son et al. (2007) [both in vitro]
Anti-atherosclerotic Moreno and Giralt (2015); Lee and Bae (2016) [both in vitro]
Anticancer (hematologic malignancies) Safaeinejad et al. (2013) [in vitro]; Mohseni-Kouchesfahani et al. (2017); Moga et al. (2018) [all performed in vitro]
Anticancer (solid tumours) Son et al. (2007); Liu et al. (2016); Park et al. (2011); Cornara et al. (2017); Ip et al. (2008); Jo et al. (2012); Kim et al. (2015a);
Oršolić (2009); Choi et al. (2014); Gajski et al. (2016); Tu et al. (2008); Lee et al. (2015b); Wang et al. (2015); Sisakht et al.
(2017); Jung et al. (2018); Moga et al. (2018) [all performed in vitro]
Antidiabetic Prakash and Bhargava (2014) [in vivo, humans]; Hossen et al. (2017) [in vivo, mice and rabbits];
Antimicrobial Han et al. (2016); Lee (2016); Hegazi et al. (2017); Al-Safar et al. (2018); Park et al. (2018) [all performed in vitro]
Antimutagenic Varanda et al. (1999); Cornara et al. (2017) [all performed in vitro]
Antioxidant Sobral et al. (2016); Somwongin et al. (2018) [all performed in vitro]
Antiproliferative and cytotoxic Gülmez et al. (2017); Sobral et al. (2016) [all performed in vitro]
Antiviral Hassan et al. (2015); Hood et al. (2013); Kim et al. (2015a); Wachinger et al. (1998), Jallouk et al. (2014) [all performed in vitro]
Apoptosis Moon et al. (2006); Jang et al. (2003); Park et al. (2014); Ip et al. (2008); Doo et al. (2012); Choi et al. (2014); Sisakht et al.
(2017) [all performed in vitro]
Alleviating post-stroke shoulder pain Cho et al. (2013a) [in vivo, humans]
Chemotherapy-induced peripheral neuropathy Park et al. (2012); Yoon et al. (2012) [in vivo, humans]
Chronic osteoarticular pain Shin et al. (2012); Seo et al. (2017) [in vivo, humans]
Complex regional pain syndrome Kim et al. (2014) [in vivo, humans]
Depression El-Wahab et al. (2015); Cherniack and Govorushko (2018) [in vivo, humans]
Lateral epicondylitis of the elbow Jung et al. (2014) [in vivo, humans]
Neuro-protective Doo et al. (2012); Jung et al. (2015); Hwang et al., 2015 [all performed in vitro]
Parkinson's disease Cho et al. (2018); Hwang et al., 2015; Ostrovsky and Ehrlich (2018); Kim and Jeon (2014); Lee and Bae (2016) [in vivo, humans]
Periodontitis Kim et al. (2018); Gu et al. (2019) [both in vitro]
Postherpetic neuralgia Lee et al. (2014a) [in vivo, humans]
Radio-protective Cornara et al. (2017); Gajski et al. (2016) [in vitro]
Rheumatoid arthritis Son et al. (2007); Lee et al. (2003); Lee et al. (2003a); Brito et al. (2018) [all performed in vivo, using animal models]
Sexual dysfunction Lee and Yu (2014) [in vivo, humans]
Skin disease (acne vulgaris) Han et al. (2013a); Han et al. (2016a); Kim et al. (2015) [in vitro, in humans];
Fig. 2. Graphical overview of apitoxin composition, strengths, weaknesses, opportunities and threats.
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Han et al. (2013a) observed that cosmetics containing purified BV
had a better efficiency in reducing microorganisms’ concentration and
the number of skin lesion, suggesting that purified BV could be a good
candidate for developing new formulations for acne vulgaris treatment.
Later, Han et al. (2015) made it possible to objectify BV efficacy in
terms of reducing wrinkle count, area, and depth in subjects with
photodamaged skin. Also, these authors stated that the irritation po-
tential is negligible and that long-term treatment with bee venom-
containing cosmetics was safe.
Current, the majority of the cosmetic products available on the
market do not mention exactly the content of BV, being marketed as
containing “purified bee venom” or “bee venom extracts” without fur-
ther specification. Efforts must be done in order to invest in products’
standardization and labelling, in order to overcome this very important
limitation. Indeed, a method for the detection and quantification of
melittin, as a marker of BV concentration, was developed by Tusiimire
et al. (2015).
5. Bee venom: safety and practical considerations
During the bee sting a small amount of BV is injected into the victim
(maximum of 0.3 mg per sting). The severe allergic reactions, which
among insects are most frequently induced by the order hymenoptera,
are more often related to IgE-mediated reactions induced by allergens
rather than to the direct toxic activity of other venom components (dos
Santos-Pinto et al., 2018). To date, the main allergens found in BV are
phospholipase A2 (Api m1), hyaluronidase (Api m2), acid phospho-
monoesterase (Api m3), melittin (Api m4), dipeptidyl dipeptidase IV
(Api m5), protease inhibitor (Api m6), CUB serine protease 1 (Api m7),
carboxylesterase (Api m8), serine carboxypeptidase (Api m9), icarapin
(Api m10), major royal jelly protein 9 (Api m 11.0101 & Api m
11.0201) and vitellogenin (Api m12) (Kołaczek et al., 2017). According
to the International Union of Immunological Societies (IUIS), Phos-
pholipase A2, hyaluronidase and apamin are the major allergens con-
tained in BV (Tusiimire et al., 2015; Park et al., 2013; Lee et al., 2018).
These compounds induce changes in cell membranes, degrade hya-
luronic acid, enhance toxins’ spreading into tissues and play a role in
the destruction of extracellular matrix, among other mechanisms
(Reitinger et al., 2008).
According to the literature, more than 50% of the general popula-
tion has IgE reactivity to the major allergens of BV which can cause a
spectrum of allergic reactions, which usually appear within 10min
(Vazquez-Revuelta and Madrigal-Burgaleta, 2018). The reactions in-
duced by BV affect the skin but also the gastrointestinal, respiratory and
cardiovascular systems, ranging from mild, local swelling to systemic
and severe reactions that in some cases can even be life-threatening
(Marković-Housley et al., 2000).
Even though it has been reported that venom immunotherapy is
effective in the majority of Hymenoptera venom allergic patients, early
and late side effects to the injections have been found in 20–40% of the
patients (Blank et al., 2013). The most common early side effect is the
acute local reaction, followed by weakness and dyspnoea; rhinitis and
abdominal pain are more common as late side effects (Kołaczek et al.,
2017).
In order to ensure patients’ safety and to take advantage of the
potentialities of BV while reducing the side effects, some researchers
suggest the removal of the allergens PLA2, hyaluronidase, acid phos-
phomonoesterase and apamin (Brito et al., 2018). In that context, Lee
et al. (2018) developed an effective strategy for MLT purification from
BV which also effectively removed PLA2 and apamin. Also, Park et al.
(2013) found that the use of 50% ethanol aqueous solution for the
purification and analysis of BV, the content of apamin and other al-
lergens was significantly decreased, yet MLT was kept stable. In addi-
tion, Lee et al. (2015c) and Brito et al. (2018), by means of ultra-
filtration using 10 kDa molecular weight cut-off filters, made it possible
to effectively remove PLA2.
Even though BV has promising healing properties it may cause sev-
eral adverse events, whose occurrence is mostly unpredictable. Local
inflammatory but also systemic reactions, among which erythema,
pruritus, swelling, pain, anaphylaxis, neurological complications among
other nonspecific reactions may occur (Yang et al., 2017). Therefore, the
researchers and health care practitioners must be aware and pay careful
attention to the safety rules regarding the BV concentration and amounts
to be administered in the patients (Zhang et al., 2018).
The beehive products have been used in the human therapeutic
activities since memorable times. Concretely, the practices of acu-
puncture using the venom have been extensively used in Oriental
medicine even though their effectiveness and safety profile is still
controversial due to the limited evidence (Zhang et al., 2018).
In our days, the toxicity of BV it is a big dilemma for the researchers.
Several authors reported that BV is safe for humans, allowing to take
advantage of its antimicrobial (Uddin et al., 2016), anti-inflammatory,
anti-wrinkle (Lee et al., 2015c), and anti-acne properties (Han et al.,
2016a), among others. The topical application of BV is advantageous to
the residual harmful systemic side effects (Nitecka-Buchta et al., 2014).
On the other hand, several other studies raised concerns on BV toxicity
(Lee et al., 2015c; Kołaczek et al., 2017). A meta-analysis performed in
2015, including 145 studies, revealed that the median frequency of
patients experiencing adverse events associated with BV im-
munotherapy was 29% (in the audit studies); and BV acupuncture had a
261% increased relative risk for the occurrence of adverse events, in
comparison with normal saline injection (Park et al., 2015). Systemic
reactions occurred in 14% of the patients, half of which were severe.
This study concluded that adverse events related to bee venom therapy
are frequent, suggesting that safety is still a limitation to take into
consideration.
Gülmez et al. (2017) reported that BV is highly toxic to cancer cells
but also to non-tumorigenic cells, suggesting that the use of BV in the
treatment of malignant tumours should be re-evaluated due to the
undesirable cytotoxicity; further studies must be performed to clarify
this issue.
Recently, a case reported raised a major issue. A Spanish women of
55 years age, without clinical records of any disorder, risk factors or
previous reactions of any kind to Hymenoptera, had been attending
apitherapy sessions for two years with good tolerance. One day, im-
mediately after a live bee sting the women suddenly developed dys-
pnoea, wheezing and loss of consciousness and, due to multiorgan
failure, died a few weeks later (Vazquez-Revuelta and Madrigal-
Burgaleta, 2018). According to the researchers this case is the first re-
port of death associated to the BV therapy due to complications of se-
vere anaphylaxis.
A recent in vivo study performed in 2018, using mice, reported that
the approximate median lethal dose (LD50) of the BV is 13.19mg/kg
(Lashein et al., 2018). The amount of BV released during a bee sting
ranges between 50 and 140 μg (Moreno and Giralt, 2015), much lower
than the average lethal dose. However, as previously described, it may
be sufficient to trigger an anaphylactic reaction. Therefore, for each
therapeutic use the optimal dose and application method must be de-
termined, in order to ensure that the beneficial effects are not hampered
by harmful adverse reactions.
Last but not the least, it is essential to ensure the safety and quality
of the BV: before use, a battery of physicochemical and microbiological
analysis must be performed. Attention must be paid also on the storage
conditions: BV may be stored up to 12months at room temperature or
up to 24 months if kept in a cool place (2-8 °C), in the original con-
tainer, unopened, in a dry place and away from strong light (Lee et al.,
2015a).
6. Conclusions
Bee venom has been used since the ancient times in the treatment of
different disorders. On the last decades, several studies provided
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scientific evidence regarding the wide range of biological activities of
Apitoxin. In spite of that, the adverse effects that not uncommonly
follow BV administration are still a challenge for researchers and
healthcare practitioners worldwide. Indeed, even though BV im-
munotherapy appears to be efficacious and safe (when used in con-
trolled conditions), side effects related to BV therapy cannot be un-
derscored. In addition, the generation of clinical-grade and sterile
pharmaceutical products derived from BV is still challenging, mostly
related to identification, isolation, and purification of bioactive com-
ponents; further developments are expected. In the future, practitioners
should be trained in order to optimize the BV concentrations that allow
maximising the clinical beneficial effects while avoiding adverse ones;
further studies (mainly randomized controlled trials) are required.
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